Cardiotoxicity: a challenge for modern oncology

Cardiotoxicity: a challenge for modern oncology

The article provides a modern vision of the problem of cardiotoxicity in oncology. Integrity and generality of nodal pathogenetic events in the body in case of carcinogenesis, antitumor therapy and cardiopathology are caused by similar mechanisms at different hierarchical levels. Identity of potenti...

Full description

Bibliographic Details
Main Authors:	Oleg I. Kit, Elena M. Frantsiyants, Elena A. Djenkova, Oksana V. Katelnitskaya, Alla I. Shikhlyarova, Aleksandr B. Sagakyants, Ekaterina V. Verenikina, Yuriy А. Gevorkyan, Yuriy А. Fomenko, Vladimir S. Trifanov, Aleksey N. Shevchenko
Format:	Article
Language:	English
Published:	Russian New University 2018-11-01
Series:	Cardiometry
Subjects:	Cardiotoxicity Cardiopathology Carcinogenesis Trastuzumab Tissue homeostasis Antitumor effect
Online Access:	http://www.cardiometry.net/issues/cardiotoxicity

Similar Items

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
by: Martin Nicol, et al.
Published: (2021-04-01)

Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis
by: Xinyi Li, et al.
Published: (2021-08-01)

Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer
by: Marinko Tanja, et al.
Published: (2018-02-01)

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
by: Claudia Altomare, et al.
Published: (2021-04-01)

Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Wesam Abdel-Razaq, et al.
Published: (2019-01-01)

Cardiotoxicity Associated with Trastuzumab Therapy in Taiwan: A Single Medical Center's 5-Year Experience
by: Che-Ming Chang, et al.
Published: (2015-06-01)

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
by: Santino Minichillo, et al.
Published: (2017-11-01)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
by: Iacopo Fabiani, et al.
Published: (2020-08-01)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
by: Mayuko Ito, et al.
Published: (2021-02-01)

Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity
by: Gao L, et al.
Published: (2021-05-01)

Pathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents
by: Aleksey M. Chaulin, et al.
Published: (2020-09-01)

Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy
by: Márcio Vinícius Lins de Barros, et al.
Published: (2018-12-01)

Cardioprotective effect of green tea extract and vitamin E on Cisplatin-induced cardiotoxicity in mice: Toxicological, histological and immunohistochemical studies
by: Mahrous A. Ibrahim, et al.
Published: (2019-05-01)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
by: Isabel Blancas, et al.
Published: (2020-12-01)

Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
by: Coppola C, et al.
Published: (2016-11-01)

The mechanistic insights of the arrhythmogenic effect of trastuzumab
by: Natthaphat Siri-Angkul, et al.
Published: (2021-07-01)

Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
by: Melissa Y. Y. Moey, et al.
Published: (2019-07-01)

Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity
by: Olufunke Esan Olorundare, et al.
Published: (2021-03-01)

Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure
by: Nadine Norton, et al.
Published: (2020-08-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study
by: Ashita Barthur, et al.
Published: (2017-04-01)

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
by: Louise Hiller, et al.
Published: (2018-04-01)

Cardiotoxicity Complication of Radiotherapy
by: Beta Agustia Wisman, et al.
Published: (2017-12-01)

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
by: Nathalie I. Bouwer, et al.
Published: (2020-08-01)

CHEMOTHERAPY CARDIOTOXICITY SCREENING WITH CARDIAC TROPONINS
by: O. V. Krikunova, et al.
Published: (2015-12-01)

Carbamazepine Cardiotoxicity
by: J Gordon Millichap
Published: (1993-10-01)

Cardiovascular toxicities from systemic breast cancer therapy
by: Shuang eGuo, et al.
Published: (2014-12-01)

Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial
by: Joannes A.A. Reijers, et al.
Published: (2015-08-01)

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI
by: Ezekowitz Justin, et al.
Published: (2011-07-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

Cardio-Оncology – New Challenge in Clinical Practice
by: Sladjana Popović, Srdjan Popović, Nikolina Dukić, Jelena Vladičić-Mašić, Olivera Čančar
Published: (2020-06-01)

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
by: Gennaro Riccio, et al.
Published: (2018-02-01)

Cardiotoxicity of Anticancer Therapeutics
by: Jerry Dong, et al.
Published: (2018-02-01)

The prospects for applications of cardiometric approach in evaluation of cardiotoxicity under Anthracyclines therapy in patients with breast cancer
by: Alla I. Shikhlyarova, et al.
Published: (2018-11-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I
by: Chazova I.Ye., et al.
Published: (2017-09-01)

Anthracycline Cardiotoxicity
by: Umberto Campia, MD, MSc, et al.
Published: (2020-06-01)

Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft
by: Anni Pan, et al.
Published: (2018-01-01)

Cardiotoxicity and Mechanisms of Immune Checkpoint Inhibitors
by: DONG Shuang, et al.
Published: (2018-11-01)